Sales Of This Eli Lilly Drug Could Nearly Double Wall St. Consensus In 2020, SunTrust Predicts
June 24, 2015 at 11:09 AM EDT
In a report published Wednesday, SunTrust Robinson Humphrey analyst John T. Boris reiterated a Buy rating and $95 price target on Eli ...
